Effect of a bovine hemoglobin preparation (SBHS) on the response of two murine solid tumors to radiation therapy or chemotherapeutic alkylating agents

Biomater Artif Cells Immobilization Biotechnol. 1992;20(2-4):657-60. doi: 10.3109/10731199209119697.

Abstract

When tested in mice bearing the Lewis lung tumor with 2, 3, or 4 Gy daily for 5 days, SBHS produced a dose-modifying factor of 1.6 that was increased to 2.1 with carbogen. The addition of SBHS (1.32 gm protein/kg) to treatment with melphalan (MEL) resulted in a 2.2-fold increase in the tumor growth delay (TGD). The combination of SBHS with carbogen (6 h) produced a 3.6-fold increase in TGD compared with MEL alone. The addition of SBHS to treatment with cyclophosphamide (CTX) resulted in a 2-fold increase in the TGD. However, the combination of SBHS and carbogen was much more effective resulting in a 4.6-fold increase in TGD. There was a 1.3-fold increase in TGD with SBHS and CDDP compared with CDDP alone. The combination of SBHS and carbogen was a more effective addition to CDDP resulting in a 1.9-fold increase in TGD. The addition of SBHS to treatment with BCNU increased the TGD produced by BCNU by 1.5-fold. The combination of SBHS/BCNU and carbogen resulted in a 2.3-fold increase in TGD over that obtained with BCNU alone.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alkylating Agents / therapeutic use
  • Animals
  • Blood Substitutes / isolation & purification
  • Blood Substitutes / therapeutic use*
  • Combined Modality Therapy
  • Hemoglobins / isolation & purification
  • Hemoglobins / therapeutic use*
  • Male
  • Mice
  • Mice, Inbred C3H
  • Mice, Inbred C57BL
  • Neoplasms, Experimental / drug therapy
  • Neoplasms, Experimental / radiotherapy
  • Neoplasms, Experimental / therapy*

Substances

  • Alkylating Agents
  • Blood Substitutes
  • Hemoglobins